Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(1):6-7; doi:10.1093/jnci/94.1.6
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Dolan, M. E.
Right arrow Articles by Schilsky, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dolan, M. E.
Right arrow Articles by Schilsky, R. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 1, 6-7, January 2, 2002
© 2002 Oxford University Press

EDITORIAL

Silence Is Golden: Gene Hypermethylation and Survival in Large-Cell Lymphoma

M. Eileen Dolan, Richard L. Schilsky

Affiliation of authors: Section of Hematology–Oncology, Department of Medicine, Committee on Clinical Pharmacology, Committee on Cancer Biology, Cancer Research Center, University of Chicago, IL.

Correspondence to: M. Eileen Dolan, Ph.D., Section of Hematology–Oncology, 5841 S. Maryland Ave., Box MC2115, University of Chicago, Chicago, IL 60637 (e-mail: edolan@medicine.bsd.uchicago.edu).

Much effort has been directed at identifying molecular markers in human tumors that predict response and/or survival after treatment with chemotherapeutic agents. Molecular predictors help to identify patients most likely to benefit from a particular therapy, with the ultimate goal of selecting optimal treatment for each patient. Gene microarray analysis has already identified genes that may be useful for predicting the clinical behavior of certain tumors (1,2). In malignant lymphoma, microarray analysis has clearly identified subgroups of tumors within the category of diffuse large B-cell lymphoma (B-DLCL) that are histologically indistinguishable but differ considerably in outcome after treatment with standard therapies (3). The specific genes responsible for the different outcomes have not yet been identified. In this issue of the Journal, Esteller et al. (. . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?